vatalanib has been researched along with bisacodyl in 1 studies
Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (bisacodyl) | Trials (bisacodyl) | Recent Studies (post-2010) (bisacodyl) |
---|---|---|---|---|---|
276 | 42 | 98 | 483 | 142 | 144 |
Protein | Taxonomy | vatalanib (IC50) | bisacodyl (IC50) |
---|---|---|---|
G-protein coupled receptor 55 | Homo sapiens (human) | 0.9084 | |
Cytochrome P450 2C9 | Homo sapiens (human) | 10 | |
Kappa-type opioid receptor | Homo sapiens (human) | 2.437 | |
Sodium-dependent dopamine transporter | Homo sapiens (human) | 2.208 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
1 other study(ies) available for vatalanib and bisacodyl
Article | Year |
---|---|
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |